healthcare

Novartis is wagering high on gene therapy with its proposed acquisit ion of AveXis Inc. valued at $8.7 billion. The high-premium deal is expected to be completed in mid-2018. Source https://news.alphastreet.com/novartis-avexis-a-gene-ius-deal/ "The pharmaceutical sector is witnessing many...

All good things come to an end — and that includes Pfizer’s run with its blockbuster drug Viagra. The drugmaker’s little blue pill did help many deal with erectile dysfunctions (and then some more!) while generating billions for the company in its two decades. With no more exclusive rights to...

Pfizer (PFE) has been contemplating on selling its consumer healthcare division for some time, and it had found two bidders - British pharmaceutical giants GlaxoSmithKline and Reckitt Benckiser. However, with Reckitt announcing its decision to back out of the race yesterday to pursue its $16.6...

It’s no big secret that investment in biotech stocks can offer great returns for investors, and at the same time, they can do some serious damage also. Some of these companies not just tackle serious issues like cancer, but also prove to be a life-saving medicine in an investor’s portfolio...

The latest study on the data retrieved from a few international organizations looked at the healthcare expenditures and performance outcome throughout the world. They made a comparison between the U.S. and other high-income countries. Researchers found that the major factors for the vast...

There is a lot to look forward to as Mylan reports earnings aftermarket today. The stock has been up 9.65% since it reported last quarter results. Market pundits expect earnings to be lower this quarter, complemented by a sales decline of 0.80%...

If you ask Sansa Stark from HBO’s Game of Thrones, she’ll tell you the best way to go is to team up with someone strong or risk getting killed. And that’s what happens to most acquisitions in the market nowadays. Over the past three years or so, we have seen a plethora of deal announcements...

http://alph.st/b9cac1fc UnitedHealth's profits more than doubled in the fourth quarter to $3.61Bil due to tax benefits. $UNH also crossed $200Bil mark in revenues for FY17. The company now expects to save $1.7Bil in FY18 due to tax reforms. For 2018, the health insurer expects GAAP EPS between...

Revenue and profit down 4% each; US was negatively impacted by hurricanes, while other regions posted positive results. Better performance despite severe hurricanes and wildfires; also reiterated its outlook for the year. Source

Technology continues penetrating the healthcare sphere, providing physicians with comprehensive solutions able to improve patient care. Radiologists, in particular may choose from a wealth of imaging systems to store and share images: 1. Picture archiving and communication systems (PACS); 2...

Alexion's Soliris (eculizumab) product sales up 4% to $756 mil during the September quarter. Hope the FDA approval for Soliris for Myasthenia Gravis patients will boost the sales in the coming months. My granny has this disorder. I don't know when this drug will be available in the market?

Amidst concern over an emerging competition for its da Vinci Surgical Systems, Intuitive Surgical posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for TransEnterix to market its Senhance Surgical Robotic System, the first...

Danaher has successfully transformed itself into a healthcare company with broader presence in the healthcare and dental markets. With its aggressive acquisition strategy being a strong profit churner, the company saw half of its revenue growth in its recent quarter coming from the acquisitions...

Medtronic posted a 9.4% YoY increase in profit to $1.02 bln, or $0.74 per share, for the first quarter of 2018. The company generated most of its sales from heart devices, spinal implants and insulin pumps, resulting in a 3.1% growth in revenue to $7.4 bln. Earnings Infographic...

At an AIDS conference in Paris on July 24, 2017, Johnson&Johnson announced updates on its developmental AIDS drug. And guess what, it's good news!

At the 9th IAS Conference on HIV Science, JNJ announced results of its clinical trials on AIDS vaccine. And guess what? It's good news. This is huge!

Is this deal advantageous for Celgene? BeiGene (ADR) has surged nearly 28% as of now.